Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 4

1(25.0%)

4Total

N/A(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02573168Not ApplicableCompleted

Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics

Role: collaborator

NCT02466477Phase 4Completed

Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder

Role: lead

NCT02109939Not ApplicableCompleted

Genomics Used to Improve DEpression Decisions

Role: lead

NCT01632267Completed

Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

Role: lead

NCT01261364Not ApplicableCompleted

Pharmacogenetic-Directed Treatment for Major Depression

Role: lead

All 5 trials loaded